Results 201 to 210 of about 6,585,193 (310)

Risk-Based Approach for Defining Retest Dates for Active Pharmaceutical Ingredients and Excipients. [PDF]

Pharmaceuticals (Basel)
Charoo NA, Akanji O, Rahman Z, Khan AA, Badshah A.   +4 more
europepmc   +1 more source

Assessment of a Risk-Based Approach for Triaging Mammography Examinations During Periods of Reduced Capacity.

JAMA Netw Open, 2021
Miglioretti DL, Bissell MCS, Kerlikowske K, Buist DSM, Cummings SR, Henderson LM, Onega T, O'Meara ES, Rauscher GH, Sprague BL, Tosteson ANA, Wernli KJ, Lee JM, Lee CI.   +13 more
europepmc   +1 more source

An optimal posttreatment surveillance strategy for cancer survivors based on an individualized risk-based approach. [PDF]

Nat Commun, 2020
Zhou GQ, Wu CF, Deng B, Gao TS, Lv JW, Lin L, Chen FP, Kou J, Zhang ZX, Huang XD, Zheng ZQ, Ma J, Liang JH, Sun Y.   +13 more
europepmc   +1 more source

A risk-based approach to quality assurance: outcomes of consultation and next steps [PDF]

, 2012

core  

Nuclear pore links Fob1‐dependent rDNA damage relocation to lifespan control

FEBS Open Bio, EarlyView.
Damaged rDNA accumulates at a specific perinuclear interface that couples nucleolar escape with nuclear envelope association. Nuclear pores at this site help inhibit Fob1‐induced rDNA instability. This spatial organization of damage handling supports a functional link between nuclear architecture, rDNA stability, and replicative lifespan in yeast.
Yamato Okada, Mina Iwaki, Kyosuke Hagiri, Rei Izumi, Masahiko Harata, Chihiro Horigome   +5 more
wiley   +1 more source

Abstract Versus Concrete Risk Identification in Clinical Research in Japan: Randomized and Prospective Pilot Research on the Effect of Risk Reduction Activities in a Risk-Based Approach. [PDF]

Ther Innov Regul Sci
Kondo H, Chiu SW, Hayashi Y, Takahashi N, Yamaguchi T.   +4 more
europepmc   +1 more source

The RABBIT risk-based approach to clinical implementation of new technology: SRS as a case study. [PDF]

Tech Innov Patient Support Radiat Oncol, 2020
Ralston A, Graham P, Poder J, Yuen J.
europepmc   +1 more source

A light‐triggered Time‐Resolved X‐ray Solution Scattering (TR‐XSS) workflow with application to protein conformational dynamics

FEBS Open Bio, EarlyView.
Time‐resolved X‐ray solution scattering captures how proteins change shape in real time under near‐native conditions. This article presents a practical workflow for light‐triggered TR‐XSS experiments, from data collection to structural refinement. Using a calcium‐transporting membrane protein as an example, the approach can be broadly applied to study ...
Fatemeh Sabzian‐Molaei, Fredrik Orädd, Konstantinos Magkakis, Magnus Andersson   +3 more
wiley   +1 more source

Correction to: A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance. [PDF]

Adv Ther
Vemula GK, Badale P, Mavrogenis P, Lalande-Luesink I, Borkowski M, Lewis DJ.   +5 more
europepmc   +1 more source

Applicability of mitotic figure counting by deep learning: a development and pan‐cancer validation study

FEBS Open Bio, EarlyView.
In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes, Maria X. Isaksen, Frida Julbø, Manohar Pradhan, Andreas Kleppe, Sepp De Raedt, Ole‐Johan Skrede, Turid Torheim, John Arne Nesheim, Hans Martin Mohn, Hanne A. Askautrud, Karolina Cyll, Wanja Kildal, Emma Rewcastle, Melinda Lillesand, Vebjørn Kvikstad, Emiel Janssen, Robert Jones, Odd Terje Brustugun, Bjørn Brennhovd, Erik Skaaheim Haug, Lill‐Tove Rasmussen Busund, Elin Richardsen, Sigve Andersen, Tom Dønnem, Kristina Lindemann, Gunnar Kristensen, Neil A. Shepherd, Marco Novelli, Knut Liestøl, David Kerr, Håvard E. Danielsen, Tarjei S. Hveem   +32 more
wiley   +1 more source